The NCPE believe that, at the submitted price, enzalutamide is not cost effective for the treatment of adults with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel
The NCPE consider this to be a cost effective product for the defined patient population in combination with psychosocial intervention.
The NCPE believe that, at the submitted price, Abiraterone Acetate (Zytiga®) is not cost effective for the treatment of metastatic castration resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
Eltrombopag (Revolade®) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy Rapid Review Commenced Completed Outcome 10/01/2014 13/02/2014 Full Pharmacoeconomic Evaluation not Recommended.
The NCPE believe that when compared to alternative biological agents aflibercept may be considered cost saving.
The NCPE does not recommend reimbursement of vismodegib.
The NCPE do not recommend Duodopa at the current price
The NCPE do not recommend reimbursement of dapagliflozin.
The NCPE do not recommend reimbursement of Subcutaneous Abatacept (Orencia®) at the submitted price.
Pregabalin is currently reimbursed. The NCPE consider that it may be cost effective under certain assumptions.